Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
Journal of Clinical Medicine,
Год журнала:
2023,
Номер
12(13), С. 4274 - 4274
Опубликована: Июнь 26, 2023
Multiple
sclerosis
(MS)
is
a
chronic
autoimmune
disease
that
impacts
the
central
nervous
system
and
can
result
in
disability.
Although
prevalence
of
MS
has
increased
India,
diagnosis
treatment
continue
to
be
difficult
due
several
factors.
The
present
study
examines
difficulties
detecting
treating
multiple
India.
A
lack
knowledge
among
healthcare
professionals
general
public,
which
delays
treatment,
one
significant
issues.
Inadequate
numbers
neurologists
with
management
also
exacerbate
situation.
In
addition,
medications
are
expensive
not
covered
by
insurance,
making
them
inaccessible
most
patients.
Due
absence
established
protocols
standards
for
care,
India’s
techniques
vary.
population
diversity
poses
unique
challenges
regarding
genetic
variations,
cellular
molecular
abnormalities,
potential
differing
responses.
more
accurately
diagnose
monitor
specialized
medical
supplies
diagnostic
instruments.
Improved
awareness
education
as
well
development
standardized
regimens
investment
research
infrastructure,
required
address
these
By
addressing
issues,
it
anticipated
India
will
improve,
leading
better
outcomes
those
affected
this
condition.
Язык: Английский
Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications
European Journal of Medicinal Chemistry,
Год журнала:
2024,
Номер
271, С. 116446 - 116446
Опубликована: Апрель 26, 2024
Язык: Английский
Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data
Pharmacological Reports,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 9, 2025
Abstract
Background
The
treatment
landscape
for
Multiple
Sclerosis
(MS)
has
increased
significantly
over
the
past
few
decades,
thanks
to
introduction
of
disease-modifying
therapies
(DMTs).
Fingolimod,
siponimod,
ozanimod,
and
ponesimod
belong
newer
generation
oral
DMTs
categorized
as
sphingosine
1-phosphate
receptor
modulators
(S1PRMs).
Because
their
mechanism
action,
they
may
increase
risk
lymphopenia,
which
could
influence
therapeutic
management
people
with
MS.
aim
this
study
was
describe
compare
reporting
frequency
lymphopenia
related
four
S1PRMs.
Methods
Individual
case
safety
reports
(ICSRs)
were
retrieved
from
European
spontaneous
system
database
(EudraVigilance)
January
1st,
2022,
December
31st,
2023.
odds
ratios
(RORs)
computed
probability
between
a
S1PRM
versus
each
other.
Results
We
4017
ICSRs,
521
(13%)
reported
associated
fingolimod
(53.3%),
siponimod
(38.4%),
ozanimod
(5.4%),
(2.1%).
most
common
source
healthcare
professional
(94.2%),
more
than
half
ICSRs
(62.6%)
serious
lymphopenia.
Fingolimod
lower
compared
siponimod.
Both
higher
ozanimod;
also
had
in
comparison
ponesimod.
Conclusions
relevant
clinical
implication
disproportionality
analysis
is
awareness
these
drugs,
thus
supporting
proactive
monitoring
optimizing
strategies
Clinical
trial
number
Not
applicable.
Язык: Английский
1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management
International Immunopharmacology,
Год журнала:
2024,
Номер
131, С. 111835 - 111835
Опубликована: Март 19, 2024
Язык: Английский
Sphingosine-1-Phosphate Receptor Modulator – Siponimod: An Evaluation to Ameliorate Aluminium Chloride Induced Behavioural Change and Biochemical effects
Research Journal of Pharmacy and Technology,
Год журнала:
2024,
Номер
unknown, С. 179 - 187
Опубликована: Янв. 19, 2024
Introduction:
Alzheimer's
disease
(AD)
is
a
neurodegenerative
condition
characterised
by
the
gradual
loss
of
hippocampal
and
cortical
neurons,
resulting
in
diminished
memory
cognitive
function.
Siponimod
(SPM)
selective
modulator
sphingosine
1-phosphate
receptor
subtype
1
5(S1P1,S1P5
receptors),
was
found
to
have
neuroprotective
effect
neurological
disorders.
The
present
study
conducted
evaluate
its
beneficial
effects
AD.
Materials
Methods:
In-silico
molecular
docking
dynamic
simulation
studies
were
carried
know
potential
interactions
with
selected
target
proteins.
In-vivo
inthirty
rats
divided
randomly
into
five
groups
six
per
group:
Control
group
received
Carboxy
methyl
cellulose;
administered
aluminium
chloride
(AlCl3);standard
rivastigmine
(RVST)
AlCl3;
test
SPM
(0.05mg/kg
0.2mg/kg)
AlCl3.
Morris
water
maze
elevated
plus
used
learning
memory.
Behavioural
changes
biochemical
parameters
estimation
performed
at
end
experiment.
Results:
using
protein
ligands
showed
higher
score
stable
acetylcholinesterase
(AChE)
SPM.Behavioural
showed:
decrease
transfer
latency
time
maze;
reach
platform
increase
spent
quadrant
treated
rats.
Biochemical
evaluation
marked
malondialdehyde
(MDA),
nitrite,
myeloperoxidase
(MPO)levels
increased
antioxidant
levels
groups.
exhibited
significant
inhibitory
activity
onAChE.
Conclusion:
be
effective
ameliorating
AlCl3
induced
observed
benefits
restoring
attributed
on
AChE
ability
suppress
free
radical
mediated
oxidative
damage.
Язык: Английский
Assessment of Stx-1A gene polymorphism (rs1569061) in relation to the development of multiple sclerosis in Egyptian patients
Egyptian journal of Immunology,
Год журнала:
2024,
Номер
31(02), С. 18 - 27
Опубликована: Апрель 1, 2024
Multiple
sclerosis
(MS)
is
a
multifactorial
polygenic
disease;
results
from
autoimmune
and
neurodegenerative
processes
which
lead
to
multifocal
lesions
of
the
central
nervous
system.
Axonal
degeneration
was
found
be
prominent
in
inflammation
period
MS
contribute
progression
disability.
Soluble
N-ethylmaleimide
sensitive
factor
attachment
receptor
(SNARE)
complex
plays
vital
role
release
neurotransmitter
by
synaptic
vesicle
fusion.
Stx-1A
protein
(Stx-1A),
major
component
SNARE
complex,
widely
expressed
brain
tissue.
This
study
intended
evaluate
prevalence
gene
polymorphism
(rs1569061)
Egyptian
population
with
investigate
its
association
various
clinical
factors.
included
65
adult
patients
35
age-
sex-matched
normal
control
subjects.
Diagnosis
made
an
experienced
neurologist
according
revised
McDonald
criteria.
All
Patients
underwent
full
history
taking,
Age
onset
MS,
disease
duration,
course
degree
disability
Expanded
Disability
Status
Scale
(EDSS)
family
neurological
diseases.
genotyping
performed
TaqMan
assay
based
quantitative
real
time
(qPCR)
verified
sanger
sequencer.
Genotype
allele
frequencies
did
not
differ
significantly
between
case
groups.
No
difference
detected
when
comparing
genotype
frequency
different
parameters.
Discrepancy
minor
(MAF)
populations
noted.
In
conclusion,
our
showed
that
no
patient
as
regards
frequency.
Predicting
studied
population.
However,
discrepancy
noted
MAF
for
(rs1569061).
Язык: Английский
Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population
Advances in Clinical Neuroscience & Rehabilitation,
Год журнала:
2024,
Номер
unknown
Опубликована: Янв. 1, 2024
Язык: Английский
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme
Multiple Sclerosis Journal - Experimental Translational and Clinical,
Год журнала:
2024,
Номер
10(1)
Опубликована: Янв. 1, 2024
Background
Siponimod
is
approved
for
use
in
people
with
secondary
progressive
multiple
sclerosis
(pwSPMS).
An
integrated
digital
platform,
MSGo,
was
developed
pwSPMS
and
clinicians
to
help
navigate
the
steps
of
pre-siponimod
work-up.
Objective
To
explore
real-world
onboarding
experiences
siponimod
amongst
Australia.
Methods
Retrospective,
non-interventional,
longitudinal,
analysis
data
extracted
from
MSGo
(20
April
2022).
The
primary
endpoint
average
time
onboarding;
endpoints
were
adherence
sub-group
analyses
variables
influencing
onboarding.
Results
Mixed-cure
modelling
estimated
that
58%
participants
(
N
=
368,
females
71%,
median
age
59
years)
registered
would
ever
initiate
siponimod.
initiation
56
days
(95%
CI
[47–59]
days).
Half
cited
‘waiting
vaccination’
as
reason
delay.
Cox
regression
found
a
nominated
care
partner
had
faster
(HR
2.1,
95%
[1.5–3.0])
more
likely
continue
self-reporting
daily
dosing
than
those
without
2.2,
[1.3–3.7]).
Conclusions
Despite
limitations
self-reported
challenges
COVID-19
pandemic,
this
study
provides
insights
into
Australia
demonstrates
positive
impact
support.
Язык: Английский